Ijmrhs.com

DOI: 10.5958/j.2319-5886.2.3.091
International Journal of Medical Research
Health Sciences
www.ijmrhs.com
Volume 2 Issue 3 July - Sep
Coden: IJMRHS
Copyright @2013
ISSN: 2319-5886
Received: 23th May 2013
Revised: 24th Jun 2013
Accepted: 26th Jun 2013
COMPARATIVE STUDY OF FLUTICASONE PROPIONATE WITH BUDESONIDE AND
BECLOMETHASONE DIPROPIONATE IN MILD PERSISTENT BRONCHIAL ASTHMA
Department of pharmacology, Dr. V.R.K. Women's Medical College Teaching Hospital & ResearchCentre Aziz Nagar, R.R. District, A.P, India *Corresponding author email: [email protected] ABSTRACT
Objective: To compare the efficacy and adverse effects of fluticasone propionate with that of
budesonide and beclomethasone dipropionate in mild persistent cases of bronchial asthma. Methods:
This was an open label, randomized parallel group study done in Government General and Chest
Hospital, Hyderabad for a period of 12 weeks. Each group had 20 patients. The group I was given
fluticasone propionate inhalation therapy 100µg twice daily. Group II was given budesonide inhalation
therapy 200µg twice daily. Group III was given beclomethasone dipropionate inhalation therapy 200µg
twice daily. Results: Symptomatic improvement was observed in all three groups. At end point, mean
FEV1 in fluticasone propionate treatment group improved by 22.04% compared with 14.53% in
budesonide and 12.02% in beclomethasone treatment groups. At end point, mean FVC value of the
fluticasone propionate treatment group improved by 8.04% compared with 5.29% in budesonide and
4.27% in beclomethasone groups. Mean FEV1 / FVC also improved by 12.76% in the fluticasone
propionate group compared with 8.63 % in budesonide and 7.45 % in beclomethasone groups. No
adverse effects were reported in any of the treatment groups. Conclusion: This study showed that
fluticasone propionate is superior to budesonide and beclomethasone in improving lung function,
decreasing symptoms and need for rescue medication in mild persistent asthma
Keywords: Fluticasone, Budesonide, Beclomethasone, Mild persistent asthma
INTRODUCTION
Bronchial asthma is a chronic inflammatory exacerbations may affect activity. Night time disorder of the airways. It is characterized by symptoms > 2 times a month, FEV1 or PEF > airflow obstruction that is typically reversible 80% predicted, PEF variability 20-30%.
and by airway hyper responsiveness to various This study was done to compare the clinical efficacy of three different inhaled glucocorticoids Education and Prevention Program (NAEPP) 1,
namely fluticasone propionate, budesonide and mild persistent asthma is characterized by beclomethasone dipropionate in mild persistent symptoms > 2 times a week but < 1 time a day, Int J Med Res Helath Sci. 2013;2(3):518-522 FIGURE-5 : REDUCTION IN FREQUENCY OF USE OF RESCUE MEDICATION IN PATIENTS WITH MILD
PERSISTENT ASTHMA
S
in
e
g
n
a 72
FIGURE-6 : ASSESSMENT OF FEV1, FVC, FEV1/FVC IN PATIENTS WITH
MILD PERSISTENT ASTHMA
Fig.4: Reduction in frequency of use of rescue medication in patient with mild persistent asthma.
Fig.5: Assessment of FEV1, FVC, FEV1/FVC in patient with mild persistent asthma.
DISCUSSION
persistent asthma. They reported that fluticasone prescribed doses of inhalational steroids in mild propionate provides greater asthma control than persistent asthma. Fluticasone propionate 100µg beclomethasone dipropionate with a comparable twice daily, Budesonide 200 µg twice daily, Beclomethasone dipropionate 200 µg twice daily propionate 200 µg twice daily with budesonide significantly greater improvements in lung propionate produced significant improvement in budesonide and beclomethasone dipropionate.
pulmonary function tests was observed in both Patient compliance was good which 90% in all The present study supports the findings observed Raphael et al., 2 in a study compared two doses
in the above studies. No adverse effects were of fluticasone propionate (88 µg twice daily, 220 reported in any of the treatment groups during Int J Med Res Helath Sci. 2013;2(3):518-522 CONCLUSION
It can be concluded that fluticasone propionate issuperior to budesonide and beclomethasonedipropionate decreasing symptoms and need for rescuemedication in mild persistent asthma. Patientcompliance was good with all the three drugs.
REFERENCES
1. Tierney LM Jr, McPhee SJ. Papadakis MA, editors. CMDT. 43rd Edn. New York: LangeMedical Books/McGraw-Hill.2004; p.220-32.
2. Raphael GD, Lanier RQ, Baker J, Edwards L, Richard K, Lincourt WR. A comparison ofmultiple doses of fluticasone propionate andbeclomethasone dipropionate in subjects withpersistent asthma. J Allergy Clin Immunol.
1999; 103: 796-803.
relationship between airways inflammationand asthma severity. Am J Respir Crit CareMed. 2000; 161: 9-16.
4. Asthma Allergy & Airway Research Center.
Information for Health Care Professionals.
Asthma http://www.upmc.edu/AAARC/professionals.
htm.
5. Connolly A. A comparison of fluticasone respective powder devices in the treatment ofmild asthma. Eur J Clin Res. 1995; 7: 15-29.
Int J Med Res Helath Sci. 2013;2(3):518-522

Source: http://ijmrhs.com/vi23/30.%20Jagan%20modified.pdf